ClinicalTrials.gg
CompletedNCT02721641Updated Mar 31, 2017Results posted

A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

A Phase 3 interventional study of Herceptin in Neoplasms, sponsored by Hoffmann-La Roche. Completed at 41 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-31.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to provide continued access to intravenous (IV) Herceptin and to evaluate long-term outcomes and overall safety in participants with stable disease and human epidermal growth factor 2 (HER2)-overexpressing metastatic or locally advanced cancer who have completed a prior study with IV Herceptin.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 69 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ongoing participants from any completed global Roche-sponsored Herceptin trial
  • Participants enrolled in any Roche-sponsored Herceptin trial who have at least stable disease (or whose disease has not recurred) during Herceptin therapy at the end of the lead-in trial
  • Available study termination data (including tumor assessment and laboratory data) on the Case Report Form for the lead-in trial
  • Judged eligible by the investigator following a thorough risk/benefit assessment, if signs of chronic heart failure developed during the lead-in trial

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • Women of unless using effective as determined by the investigator
  • Severe dyspnea at rest requiring supplementary oxygen therapy
  • Severe uncontrolled systemic disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Herceptin

    Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.

    Drug: Herceptin

Interventions

  • Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. On-Study Duration of Trial Treatment

    Time frame: From date of enrollment until death or premature withdrawal (maximum 7.4 years of follow-up)

  2. Number of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) Below 45 Percent (%)

    Time frame: From date of enrollment until disease progression, death, or premature withdrawal; assessed per investigator discretion (maximum 7.4 years of follow-up)

  3. Number of Participants Withdrawn From Study Because of LVEF Dysfunction

    LVEF dysfunction was defined as low LVEF measured on two consecutive assessments, with the second assessment performed after 3 weeks of study medication being withheld. Low LVEF included values less than or equal to 39% or values between 40% and 45% (inclusive) with a decrease of 10 or more percentage points from Baseline.

    Time frame: From date of enrollment until death or premature withdrawal (maximum 7.4 years of follow-up)

07

Results

Posted Mar 31, 2017

Participant flow

Participant flow — Overall Study
MilestoneHerceptin
Started69
Completed69
Not completed0

Outcome measures

PrimaryOn-Study Duration of Trial Treatment
Time frame:
From date of enrollment until death or premature withdrawal (maximum 7.4 years of follow-up)
Reported as:
Median · days
On-Study Duration of Trial Treatment
daysHerceptin
On-Study Duration of Trial Treatment386.0 (1 to 2697)
PrimaryNumber of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) Below 45 Percent (%)
Time frame:
From date of enrollment until disease progression, death, or premature withdrawal; assessed per investigator discretion (maximum 7.4 years of follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) Below 45 Percent (%)
ParticipantsHerceptin
Number of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) Below 45 Percent (%)0
PrimaryNumber of Participants Withdrawn From Study Because of LVEF Dysfunction

LVEF dysfunction was defined as low LVEF measured on two consecutive assessments, with the second assessment performed after 3 weeks of study medication being withheld. Low LVEF included values less than or equal to 39% or values between 40% and 45% (inclusive) with a decrease of 10 or more percentage points from Baseline.

Time frame:
From date of enrollment until death or premature withdrawal (maximum 7.4 years of follow-up)
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From Study Because of LVEF Dysfunction
ParticipantsHerceptin
Number of Participants Withdrawn From Study Because of LVEF Dysfunction0

Adverse events

Collected over From date of enrollment until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment (up to approximately 7.4 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Herceptin—11/69 (15.9%)—
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventHerceptin
Arthritis bacterialInfections and infestations1/69
ErysipelasInfections and infestations1/69
Urinary tract infectionInfections and infestations1/69
NauseaGastrointestinal disorders1/69
Upper gastrointestinal haemorrhageGastrointestinal disorders1/69
VomitingGastrointestinal disorders1/69
Fibula fractureInjury, poisoning and procedural complications1/69
Lower limb fractureInjury, poisoning and procedural complications1/69
PainGeneral disorders1/69
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/69

Baseline characteristics

Age was the only demographic variable collected for the study and was only collected from 32 participants. Gender, weight, and race were not collected under the protocol.

Age, Continuous
Age, Continuous(years)Herceptin
Mean58.0 ± 11.00
Sex/Gender, Customized
Sex/Gender, Customized(participants)Herceptin
08

Study locations

41 sites
  • Liverpool, New South Wales 2170, Australia
  • Waratah, New South Wales 2298, Australia
  • Brisbane, Queensland 4006, Australia
  • Brisbane, Queensland 4066, Australia
  • Fitzroy, Victoria 3065, Australia
  • Geelong, Victoria 3220, Australia
  • Parkville, Victoria 3052, Australia
  • Brussel, 1090, Belgium
  • Beijing, 100021, China
  • Beijing, 100142, China
  • Marseille, 13273, France
  • Berlin, 12203, Germany
  • Göttingen, 37075, Germany
  • Hamburg, 20246, Germany
  • Heidelberg, 69120, Germany
  • Lübeck, 23538, Germany
  • Muenchen, 80637, Germany
  • Muenchen, 81377, Germany
  • Trier, 54290, Germany
  • Guatemala City, 01010, Guatemala
  • Budapest, 1122, Hungary
  • Debrecen, 4032, Hungary
  • Ramat Gan, 5262100, Israel
  • Bundang City, 463-802, Korea, Republic of
  • Seoul, 03080, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Auckland, 1023, New Zealand
  • Panama City, 0832-00752, Panama
  • Gdansk, 80-214, Poland
  • Lisboa, 1099-023, Portugal
  • Izhevsk, 426009, Russian Federation
  • Moscow, 115478, Russian Federation
  • Saint-Petersburg, 197758, Russian Federation
  • Belgrade, 11000, Serbia
  • Alicante, 3010, Spain
  • Barcelona, 08035, Spain
  • Edinburgh, EH4 2XU, United Kingdom
  • Glasgow, G12 0YN, United Kingdom
  • London, SE1 9RT, United Kingdom
  • Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Muller V, Clemens M, Jassem J, Al-Sakaff N, Auclair P, Nuesch E, Holloway D, Shing M, Bang YJ. Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. BMC Cancer. 2018 Mar 15;18(1):295. doi: 10.1186/s12885-018-4183-2. PubMed 29544445 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1999, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2016
First posted
Mar 29, 2016
Start
Jun 1999
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Mar 31, 2017
Last update
Mar 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02721641
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 29, 2016
Start date
Jun 1999
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Mar 31, 2017
Last update
Mar 31, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion